Search

Your search keyword '"Berdel, Wolfgang E"' showing total 2,237 results

Search Constraints

Start Over You searched for: Author "Berdel, Wolfgang E" Remove constraint Author: "Berdel, Wolfgang E" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
2,237 results on '"Berdel, Wolfgang E"'

Search Results

3. Prognostic impact of CEBPA mutational subgroups in adult AML

4. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

5. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)

6. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

7. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

8. CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process

9. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

10. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

11. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

12. Targeted siRNA nanocarrier: a platform technology for cancer treatment

15. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

16. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

17. A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy

18. Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse

19. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

20. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

21. Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia

22. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

23. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

25. A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia

26. Friday leukemia—a structural phenomenon

27. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

28. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

31. Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response

33. Prognostic impact of CEBPA mutational subgroups in adult AML

34. Deep learning predicts therapy-relevant genetics in acute myeloid leukemia from Pappenheim-stained bone marrow smears

35. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)

36. Prevalence and clinical impact of CD56 and T‐cell marker expression in acute myeloid leukaemia: A single‐centre retrospective analysis

37. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia

38. Author Correction: Loss-of-function uORF mutations in human malignancies

40. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia

41. Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia

42. The clinical mutatome of core binding factor leukemia

43. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia

45. Germline variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

46. P446: COMPREHENSIVE CHARACTERIZATION OF DIFFERENTIAL GENE EXPRESSION AND ISOFORM USAGE IN SPLICING FACTOR-MUTATED ACUTE MYELOID LEUKEMIA USING LONG-READ SEQUENCING

47. P434: MYELODYSPLASIA-RELATED MUTATIONS IN THE NEW ELN CLASSIFICATION: DOES CLONAL SIZE PLAY A ROLE?

48. P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML

49. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial

Catalog

Books, media, physical & digital resources